Pharmaceutical Executive
Consumers still aren't happy, but industry calls FDA's addition to PDUFA 'an important new step.'
Pharmaceutical Executive-01-17-2007
Pharmaceutical Executive
Novartis' upcoming anti-hypertension combo and campaign target noncompliance.
Pharmaceutical Executive
Consumers say no, and they're watching which companies are naughty or nice.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
